HomeFile

File

View Category
Antiplatelet

How to Discontinue Antiplatelet Therapy Prior Non-Cardiac Surgery

Both the indication and discontinuation of antiplatelet therapy to balance ischemic-bleeding risks has been left to physician...
solaci -
Learn More
Structural heart disease

Incidence, Predictors, and Results of Acute Kidney Injury in Patients Undergoing TAVR

Acute kidney injury after transcatheter aortic valve replacement (TAVR) is a well-known adverse event for all interventional...
solaci -
Learn More
Institutional News

06/05 | SOLACI Webinar: TAVI in Low-Risk Patients

solaci -
Learn More
Bifurcations

Watch again our Webinar “SOLACI@BIOTRONIK” on our Youtube account.

Watch again our Webinar "SOLACI@BIOTRONIK" on our Youtube account. The event was held on April 27th, 2021. 
solaci -
Learn More
Chronic Ischemic cardiopathy

[APT Medical Sponsored Clinical Case] Bilateral Distal Transradial Access for Chronic Total Occlusion Recanalization and Multivessel Coronary Disease Percutaneous Intervention

Introduction Chronic total occlusion (CTO) represents the most challenging setting for percutaneous coronary intervention (PCI) and multivessel coronary...
solaci -
Learn More
Acute coronary syndromes

Back to Basics: Ticagrelor Questioned and Clopidogrel in the Limelight

Yet another observational study has come to question the antiaggregation power of ticagrelor when it comes to...
solaci -
Learn More
Antiplatelet

Xience Receives CE Mark for Short and Ultrashort DAPT Schemes

Dual antiplatelet therapy (DAPT) one month after angioplasty with Xience stent was approved in Europe for patients...
solaci -
Learn More
Antiplatelet

Dual Antiplatelet Therapy and TAVR: Obsolete Guidelines

The current guidelines recommend dual antiplatelet therapy (DAPT) 3 to 6 months after transcatheter aortic valve replacement...
solaci -
Learn More